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Abstract: The major problems of traditional chemotherapy are non-selectivity and non-speciﬁ  city, resulting in severe toxic 
side effects. Peptides are a new-generation of drug-delivery vector to increase efﬁ  cacy of this therapy and avoid the resulting 
damage. The cytotoxic somatostatin (SST) conjugate JF-10-81 was developed by coupling camptothecin (CPT) to the 
N-terminus of a SST analog (JF-07-69) using an activated carbamate linker. This conjugate selectively targets somatostatin 
receptor subtype 2 (SSTR2) and also retains high binding afﬁ  nity and rapid internalization as well as anti-proliferative 
activity towards various tumor cells. JF-10-81 was tested for its inhibitory activity against the growth of human tumors 
which included neuroblastoma (IMR32), pancreatic cancer (CFPAC-1), leukemia (MOLT-4), pancreatic carcinoid (BON) 
and prostate cancer (PC-3). Both SSTR2 mRNAs and proteins were detected in all these tumor cell lines. The conjugate 
displayed potent in vivo inhibitory activity, although some of the potency measured in in vitro experiments was lost. JF-10-81 
was found to signiﬁ  cantly inhibit growth of these SSTR-positive tumors, resulting in 87% tumor reduction in neuroblastoma 
IMR32 and 97% in leukemia MOLT-4 bearing animals, even inducing regression of CFPAC-1 tumors. SSTR-overexpressing 
BON tumors were unfortunately relatively CPT-insensitive in vitro, however, JF-10-81 again exhibited in vivo potency 
presumably by speciﬁ  cally increasing CPT concentrations inside the tumor cells so that the inhibition rate for JF-10-81 was 
85%. Also, JF-10-81 was used to treat highly invasive PC-3 tumors where s.c. injections inhibited both tumor growth (almost 
60% reduction) and tumor metastasis (over 70%). This conjugate demonstrated its broad and excellent anti-tumor activity 
by targeting SSTR2-speciﬁ  c tumor tissues, supporting that short peptides and their analogs may be applied as ideal drug-
delivery carriers to improve the traditional chemotherapy.
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Introduction
It is hard to overemphasize the myriad drawbacks to traditional chemotherapy used in treating advanced 
or metastatic cancers. However, the major problems of non-selectivity towards tumor cells and non-
speciﬁ  city certainly rank among the likely potential causes of severe toxic side effects. Also, the instability 
and/or insolubility of cytotoxic agents in aqueous media limit their clinical application. Possible routes 
to overcome these problems and improve their therapeutic properties are numerous and include various 
new drug delivery systems such as polymer [1,2], nano-particles [3–6], antibody conjugates [7,8], and 
short peptide hormone conjugates [9–13].
Speciﬁ  c receptors for many of these peptides, the most investigated being somatostatin (SST) and 
bombesin (BM), have been found to be expressed aberrantly in various tumors [14]. Taking advantage 
of these observations, receptor-targeted cytotoxic peptide conjugates can be used to target receptor-
speciﬁ  c tumor tissues, increase efﬁ  cacy of chemotherapeutic agents and decrease severe toxic side effects 
as long as suitable cleavable linker groups can be synthesized. Hence, several peptide conjugate candi-
dates have been developed during recent years and short, easily synthesized peptides [13] were used as 
vectors to couple with chemotherapeutic agents and carry them to target receptor-speciﬁ  c tumor cells. 
In our laboratories, camptothecin (CPT), a potent anti-tumor agent [15,16], has been successfully 
coupled to urotensin, BM, and SST analogs. These new cytotoxic conjugates displayed relatively low 
toxic side effects and signiﬁ  cant inhibition to tumor cell proliferation and tumor growth [11,12,13,17]. 
Also, cytotoxic conjugates of SST [18], BM [19] and luteinizing hormone-releasing hormone (LHRH) 
[20] coupled with 2-pyrrolinodoxorubicin, have been synthesized and investigated by others. These 
conjugates showed broad and excellent anti-tumor activities [18–21]. Peptide hormones as drug-delivering 
vectors have their own speciﬁ  c advantages over other approaches such as rapid internalization (via their 492
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respective GPCRs), better tumor-penetrating ability 
and quick circulatory clearance [14].
SSTRs, especially SSTR2, have been found to 
be highly expressed in various tumors [14,22,23] 
and tumoral blood vessels [24]. The two naturally 
occurring compounds, SST-14 and SST-28, bind 
with high afﬁ  nity to all ﬁ  ve receptor subtypes 
whereas certain clinically approved SST analogs 
only selectively bind to SSTR2 while being much 
more stable in the circulation. Such analogs are 
attractive starting points for use as vectors to 
precisely deliver non-selective cytotoxic agents to 
receptor-selective target sites. For instance, CPT 
coupled to a SST analog selectively bound to 
SSTR2 and was designed to retain high binding 
afﬁ  nity even with the attachment of large drug 
molecules. This CPT-SSA conjugate JF-10-81 has 
already shown favorable anti-invasive and anti-
angiogenic activities [25]. In the current study, we 
further extend these studies to investigate the ability 
of JF-10-81 to prevent the growth of several impor-
tant tumor types by sustained delivery formulations 
and metastasis of the highly invasive prostate 
cancer PC-3 tumor by periodic injections.
Materials and Methods
Materials
The cytotoxic CPT-SST conjugate JF-10-81 was 
synthesized as described previously [9]. Continuous 
drug-releasing pellets containing JF-10-81 
(5 mg/pellet) formulated to release drug for 60 
days, were made by Innovative Research of 
America (Sarasota, FL).
Cell culture
The CHO-R1 and CHO-R2 cell lines, which were 
transfected with rat SSTR1 and SSTR2, respec-
tively, were a kind gift from Dr. Agnes Schonbrunn 
(University of Texas—Houston, Houston, TX). 
Cells were cultured in F-12 medium containing 10% 
fetal calf serum. All other human tumor cell lines, 
including neuroblastoma IMR32, leukemia 
MOLT-4, pancreatic cancer CFPAC-1, prostate 
cancer PC-3 were purchased from ATCC (American 
Type Culture Collection, Manassas, VA). Human 
pancreatic carcinoid BON cells were a kind gift 
from Dr. Courtney Townsend (University of 
Texas—Galveston) and cultured as described 
previously [9,26].
Ligand-receptor binding 
and internalization assay
The assay was performed as a modiﬁ  cation of the 
one previously described [27,28]. The binding 
buffer contained Dulbecco’s Modiﬁ  ed Eagle’s 
Medium (DMEM), 50 mM HEPES, 2 mM 
glutamine, 11.5 mM glucose, 1% bovine serum 
albumin (BSA) and 5 mM sodium pyruvate. The 
binding reactions took place in 1.5 ml eppendorf 
tubes containing 70–100 pM of [
125I]Tyr
11-SST-14 
from PerkinElmer (Boston, MA 02118-2512), 
1−1.5 × 10
5 cells and the tested SST analogs (10
−5 
to 10
−13 M) for a total volume of 300 µl. These were 
incubated at room temperature for 50–60 minutes 
and centrifuged for 1–2 min at 9,000 g. The cell 
pellets were washed twice with phosphate-buffered 
saline (PBS) and counted for total radioactivity in 
a Titertek gamma counter (Huntsville, AL). The 
analyses were done using GraphPad Prism 4.0 (San 
Diego, LA). For further internalization [29], cells 
were then re-suspended and incubated in HBSS 
(pH4, acetic acid) on ice for 10 min, washed with 
cold PBS and then re-counted for radioactivity. 
Due to the radioactivity of membrane-bound 
receptors being released by the acid wash, the 
remaining radioactivity represents the internalized 
peptide.
RT-PCR
RT-PCR reagents were purchased from Invitrogen 
(Carlsbad, CA). Total RNA from the 5 different tumor 
cells described above was isolated. The RT-PCR 
ampliﬁ  cation of the mRNAs of all 5 SSTR subtypes 
was performed under the same conditions as described 
in the reference[30] with the following primers: 
SSTR1-F: 5’-AAATGCGTCCCAGAAC-
GGGACCT-3’, SSTR1-R: 5’-CAGGTTCTCAG-
GTTGGAAGTCTT-3’; SSTR2-F:  
5’-GATGATCACCATGGCTGTG-3’, SSTR2-R: 
5’-CAGGCATGATCCCTCTTC-3’; SSTR3-F: 5’-
TCATCTGCCTCTGCTACCTG-3’, SSTR3-R: 5’-
GAGCCCAAAGAAGGCAGGCT-3’; SSTR4-F: 
5’-CATGGTCGCTATC-CAGTGCA-3’, SSTR4-R: 
5’-GTGAGACAGAAGACGCTGGTGAACAT-3’; 
SSTR5-F: 5’-GCTCTTGGTGTTCGCGGACGT-3’, 
SSTR5-R: 5’-CAGGTTGACGATGTTGACGGT-
GAAG-3’ [30]. The predicted RT-PCR product sizes 
are 993 bp to SSTR1, 892 bp to SSTR2, 221 bp to 
SSTR3, 276 bp to SSTR4 and 298 bp to SSTR5, 
respectively [30]. Experiments were done in 
triplicate.493
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Western blot
The protocol was employed as described (Santa 
Cruz, CA). Briefly, cells were harvested, 
resuspended in RIPA buffer with cocktail 
inhibitors, homogenized by passing through a 
21 gauge needle, mixed with loading buffer 
containing fresh DTT and heated for 5 min at 
95 
oC. Supernatants were loaded to run on 
8%–16% Tris-glycine gel after centrifugation at 
10,000 g. Protein was transferred from gel to 
nitrocellulose membrane which was then blocked 
with 5% fat-free milk, washed and incubated with 
SSTR2 antibody (Santa Cruz). The membrane was 
washed again and incubated with second antibody 
(Santa Cruz). Eventually, ﬁ  lms were developed 
according to the ECL system protocol (Amersham 
Biosciences, England).
Cell proliferation assay
The kits for the cell proliferation assay (MTT 
Assay) were purchased from Promega (Madison, 
WI) and the protocol was the same as described 
previously [26].
In vivo experiments
Male nude mice, 5–7 weeks of age upon arrival, 
were purchased from the National Cancer Institute 
(NCI, Frederik, MD). The animal study was 
approved by the Tulane University Health Sciences 
Center Institutional Animal Care and Use 
Committee (IACUC).
Tumor growth
The tumor tissue segments, grown from CFPAC-1, 
IMR32, MOLT-4 and BON cells injected into nude 
mice, were s.c. implanted into the ﬂ  anks of nude 
mice as described previously [9]. All the tumors were 
passaged from mouse to mouse. Tumor-carrying 
mice then were implanted with continuous drug-
releasing pellets containing 5 mg of JF-10-81.
For treatments of pancreatic cancer CFPAC-1 
tumors, mice were separated into 2 groups. Each 
mouse in the control group was implanted with a 
placebo pellet. Each mouse in the test group was 
implanted with a pellet containing JF-10-81 (5 mg/
pellet) with a drug-release time of 60 days. Tumor 
volumes were measured and bodyweights were taken 
once a week. The treatment for all other tumors 
(BON, IMR32 and MOLT-4) was the same as 
above.
Tumor metastasis
The experiment was performed as described [31] 
with modiﬁ  cation. Human prostate cancer PC-3 
cells were re-suspended in a PBS solution and 
further mixed with matrigel at a ratio of 1:3. The 
mixtures were implanted via i.p. injection at a 
volume of 200 ul (1 × 10
6 cell/ml). One week later, 
mice were divided into 3 groups of 8–9 mice each. 
The control group was treated with PBS. The test 
groups were treated with the cytotoxic conjugate 
JF-10-81 (3.5 mg/kg) by i.p. or s.c. injection, 3 times 
a week, for a total of 12 injections. Mice were 
monitored and checked each week. Eventually, 
mice were killed by over-anaesthetization and 
autopsies were performed and tumor metastasis 
investigated.
Results
High binding afﬁ  nity of the CPT-SST 
conjugate to SSTR subtype 2
Both native SST-14 (DC-44-76) acting as the con-
trol peptide and the CPT-SST conjugate JF-10-81 
were tested. As expected in CHO-R1 and CHO-R2 
cells, synthetic SST-14 exhibited high afﬁ  nity for 
SSTR1 (EC50: 1.85 nM) and SSTR2 (1.45 nM) 
(Fig. 1), no afﬁ  nity to the non-transfected CHO 
cells themselves. The vector JF-07-69 (2.35 nM) 
and its cytotoxic conjugate JF-10-81 (2.46 nM) 
displayed similar high afﬁ  nity binding to SSTR2. 
However, both of them had relatively weak binding 
afﬁ  nity to SSTR1, the EC50 values being 100 fold 
less than for SSTR2 (Fig. 1). The further internal-
ization assay showed that the conjugate JF-10-81 
could quickly internalize into the SSTR2-speciﬁ  c 
cells (data not shown). Therefore, this conjugate 
could potentially be applied for receptor-targeted 
chemotherapy.
Expression of SSTR2 in cultured 
tumor cells
It has been demonstrated that SSTRs, especially 
SSTR2, are aberrantly expressed in many tumors 
[14]. Herein, the expression of mRNAs of 
all 5 SSTRs and protein of SSTR2 in 5 tested tumor 
cells were investigated by RT-PCR and western 
blot.
As shown in Figure 2, the results of RT-PCR 
demonstrated that SSTR2 and SSTR5 mRNAs 
existed abundantly in all 5 tumor cell lines, except 494
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for a lack of SSTR5 in MOLT-4 cells. SSTR1 was 
highly expressed in BON and CFPAC-1 cells. 
CFPAC-1 cells showed the existence of mRNAs 
of all 5 SSTR subtypes, with traces of one or more 
subtypes detectable in the other cells (Fig. 2). 
Further, SSTR2 proteins (∼64 kD) were detected 
in all 5 tumor cells by western blot (Fig. 3). The 
expression of SSTR2 in all tested tumor cells was 
identical to previous reports that SSTR2 is 
abberantly expressed in these tumor tissues, thus 
conﬁ  rming that SSTR2 could be used as a speciﬁ  c 
target for JF-10-81 to treat these receptor-positive 
tumors.
Although not easily detected in many in vitro 
cultured tumor cells, binding afﬁ  nities in 5 tumor 
cells were further investigated with SST-14 which 
has high afﬁ  nity to all 5 SSTR subtypes. We found 
that BON and IMR32 cells have higher binding 
afﬁ  nity, with other 3 tumor cells showing weak 
binding to SST-14. The EC50 values were 1.45 nM 
to BON cells, 28.38 nM to IMR32, 195.36 nM to 
MOLT-4, 782.35 nM to CFPAC-1 and over 
1000 nM to PC-3, respectively.
Inhibition of the CPT-SSA conjugate 
to in vitro tumor cell proliferation
The CPT-SSA conjugate (JF-10-81) has been 
shown to have anti-angiogenic activity via a series 
of in vitro and in vivo experiments [25]. In the 
Figure 1. Binding afﬁ  nity of native SST-14 (DC-44-76), SST analog JF-07-69 (the vector) and the conjugate JF-10-81 to stably transfected 
SSTR1 and 2 in CHO cells. To SSTR1, EC50 values are 1.85 (DC-44-76), 192.3 (JF-07-69) and 866.3 nM (JF-10-81), and to SSTR2, 1.45 
(DC-44-76), 2.35 (JF-07-69) and 2.46 nM (JF-10-81), respectively.
PC-3 IMR32 BON CFPAC-1 MOLT-4
SSTR subtype SSTR subtype SSTR subtype SSTR subtype SSTR subtype
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Figure 2. Expression of mRNAs of 5 SSTR subtypes. Total RNAs were isolated for RT-PCR ampliﬁ  cation. The PCR products are 993 bp 
for SSTR1, 892 bp for SSTR2, 221 bp for SSTR3, 276 bp for SSTR4 and 298 bp for SSTR5. SSTR2 mRNA was detected in all 5 of the 
following human tumor cells: PC-3, IMR32, BON, CFPAC-1 and MOLT-4. The other four subtypes were undetectable in one or more tumor 
cell lines.495
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present study, it was tested for its inhibitory 
activity against ﬁ  ve chosen SSTR-abundant human 
tumor cell lines, including CFPAC-1, IMR32, 
MOLT-4, BON and PC-3 by using the MTT assay. 
The EC50 values found were: 2.8 nM (CPT) and 
46.1 nM (JF-10-81) in IMR32 cells, 2.0 nM (CPT) 
and 27.6 nM (JF-10-81) in MOLT-4 cells, 25.5 nM 
(CPT) and 196.8 nM (JF-10-81) in CFPAC-1 cells, 
170.8 nM (CPT) and 1233.4 nM (JF-10-81) in 
BON cells, 20.8 nM (CPT) and 453.6 nM 
(JF-10-81) in PC-3 cells (Fig. 4 and Table 1). All 
the tumor cells were relatively CPT-sensitive 
compared to CPT-insensitive BON cells. Also, 
JF-10-81 exhibited the same trends as CPT itself. 
However, generally the conjugate partly lost its 
cytotoxic activity, with its EC50 being almost 
10–20 fold less when compared to CPT itself. As 
expected, the vector peptide JF-07-69 did not work 
even at high concentrations (Fig. 4 and Table 1).
Inhibition of the CPT-SSA conjugate 
to tumor growth and metastasis
JF-10-81 was further evaluated for its ability to 
inhibit tumor growth and metastasis in these 
SSTR2-positive tumor models mentioned above. 
PC-3 tumors were treated with single injections of 
the conjugate. The others were implanted with 
continuous drug-releasing pellets (5 mg/pellet). As 
shown in Table 2 and Figures 5 and 6, JF-10-81 
(5 mg/pellet) displayed dramatic inhibitory activity 
in all tested tumors.
In the experiment using the pancreatic cancer 
(CFPAC-1) tumor cells and a treatment of 5 mg/pellet/
mouse, tumor volume in the control group increased 
from 168 ± 52 mm
3 to 2196 ± 832 mm
3 (up 1207%) 
after 4 weeks. Tumor volume in JF-10-81-treated 
group (5 mg/pellet) signiﬁ  cantly decreased from 197 
± 68 mm
3 to 44 ± 14 mm
3 (down 78%) after 4 weeks, 
the inhibition rate is  −92%. Tumor volumes decreased 
further to 8 ± 8 mm
3 (down 96%) 7 weeks later (Fig. 5 
and Table 2), with tumor disappearance in 4 out of 9 
mice. Tumors were regressed with JF-10-81 
treatment.
Inhibitory activity was also demonstrated in 
JF-10-81-treated neuroblastoma (IMR32) tumors. 
After 6 weeks, tumor volume sharply increased 
from 758 ± 292 mm
3 to 9098 ± 4929 mm
3 (up 
1100%) in the control group, but only from 
763 ± 218 mm
3 to 1854 ± 816 mm
3 (up 143%) in 
the JF-10-81-treated group (5 mg/pellet). The 
inhibitory rate was 87% (Table 2).
In the treatment of leukemia (MOLT-4) tumors, 
after 5 weeks tumor volume went from 393 ± 142 
mm
3 to 5615 ± 3143 mm
3 (up 1328%) in the con-
trol group, but just 270 ± 89 mm
3 to 430 ± 330 mm
3 
(up 59%) in the conjugate-treated group (5 mg/
pellet). The inhibitory rate was 97% (Table 2).
Notably, in the SSTR-over-expressing, but CPT-
resistant pancreatic BON tumors, JF-10-81 (5 mg/
pellet) appeared to display a much more potent 
inhibitory activity than did CPT alone (5 mg/pellet). 
IMR32 PC-3 BON CFPAC-1 MOLT-4
SSTR2
β-actin
Figure 3. Expression of SSTR2 protein (∼64 KD) detected in 5 tumor cells by western blot.
Figure 4. Cell proliferation assay using the CPT-SSA conjugate JF-10-81, 
vector JF-07-69 and CPT with human pancreatic cancer CFPAC-1 
cells.496
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The percentage increase of tumor volumes was 
755% in the control group, 71% in JF-10-81-
treated group (5 mg/pellet) (Table 2) and 278% in 
the CPT-treated group (5 mg/pellet) (data not 
shown). The inhibitory rates for JF-10-81 and CPT 
treatment are 85% and 42%, respectively.
On average, JF-10-81 clearly displayed potent 
anti-tumor activity (depending on cell type). This 
could perhaps be because this conjugate concen-
trated CPT inside tumor cells by targeting receptors 
on cell surfaces, although favorable changes in the 
metabolism and clearance of biologically active, 
conjugated CPT cannot be ruled out. Even at a 
lower dose (1 mg/pellet), JF-10-81 was efﬁ  cacious 
against pancreatic cancer CFPAC-1 tumor growth 
with the inhibitory rate reaching 56% . However, 
JF-10-81 at the same dose (1mg/pellet) did not 
work well in IMR32, MOLT-4 and BON tumor 
treatments (data not shown). These results also 
indicate that the inhibitory ability of JF-10-81 was 
dose-dependent.
The highly invasive PC-3 cells were chosen for 
anti-tumor metastasis experiments. PC-3 tumors 
in the control groups were found to metastasize to 
the gut, liver, chest, skin etc. of nude mice. How-
ever, in treated groups, we found that there was an 
obvious decrease in overall tumor metastasis, with 
no metastasis taking place in some mice. JF-10-81 
at 3.5 mg/kg blocked almost 73% of tumor 
metastasis using s.c. injections and 60% by i.p. 
injections (Fig. 6). Meanwhile, JF-10-81 was 
observed to result in an almost 60% reduction of 
primary tumor weights using s.c. administration 
and 40% by i.p. injections.
Discussion
Peptide-based receptor-targeted chemotherapy is 
one of a new generation of promising approaches 
for increasing the speciﬁ  city of cancer-cytotoxin 
treatments. Peptides might be optimal drug-delivery 
vectors due to their unique advantages which have 
been discussed [14]. Certain peptides such as SST, 
BN, LHRH or their analogs have been used to 
deliver cytotoxic compounds by taking advantage 
of the peptide receptors being aberrantly expressed 
and sometimes over-expressed in many human 
tumors and in the blood vessels around tumors 
[13,14,22,23,24,32]. Furthermore, the structure-
activity relationships of these peptides are well 
investigated and allow for attachment of large drug 
molecules using a large variety of cleavable linker 
chemistries with little or no loss of receptor afﬁ  nity 
and retention of signiﬁ  cant anti-tumor activities 
[9,10,20,21]. For example, AN-238, which was 
made by linking 2-pyrrolino-DOX to the SST 
Table 1. Effects of JF-10-81 on human tumor cell proliferation by MTT assay.
Cell Name Cancer type CPT EC50 (nM) JF-10-81 JF-07-69
IMR32 Neuroblastoma 2.82 ± 0.14 (3)
a 46.06 ± 8.47 (5) 10,000
CFPAC-1 Pancreatic cancer 25.53 ± 5.6 (6) 196.87 ± 37 (4) 10,000
BON Pancreatic carcinoid 170.86 ± 14.62 (3) 1248.7 ± 114.20(3) 10,000
PC-3 Prostate cancer 20.76 ± 2.82 (5) 453.55 ± 52.36 (3) 10,000
MOLT-4 Leukemia 1.96 ± 0.32 (5) 27.63 ± 0.88 (6) 10,000
Note: 
aMean ± SEM (n) and the experiments were separately repeated n times.
3
Figure 5. Human pancreatic cancer CFPAC-1 tumors treated with 
continuous drug-releasing pellets (5 mg/each) containing the 
conjugate JF-10-81.497
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Figure 6. Inhibition of JF-10-81 to the highly invasive prostate cancer PC-3 tumor growth and metastasis.
analog RC-121, exhibited potent anti-tumor activ-
ity by targeting tumor cells [33,34] or tumoral blood 
vessels [10]. In our previous studies, cytotoxic 
conjugates of SST and BN analogs have revealed 
some utility against tumor growth and angiogen-
esis [9,25,35]. The CPT-SST conjugate JF-10-81 
was found to be stable and readily water-soluble 
[9,25,36] and is predicted to display less systemic 
toxicity than the naked cytotoxic agent [36]. Also, 
JF-10-81 inhibited growth of SSTR-expressing 
tumors [9,11] and blocked development of angio-
genesis [25]. In addition, a number of other peptide 
conjugates have been shown to have more speciﬁ  c-
ity to tumor cells with less toxicity to normal cells 
[12,13,37,38].
In the present work, our most widely studied 
conjugate (JF-10-81) was further tested for its 
potentially broad anti-tumor activity using human 
tumors ranging through neuroblastoma, pancreatic 
cancer, pancreatic carcinoid, leukemia and prostate 
cancer. With all these tumors, as expected, RT-PCR 
and western blot revealed the presence of SSTR2. 
Table 2. Effects of JF-10-81 on growth of different kinds of human tumors by treatment with continuous drug-releasing 
pellets.
Tumor type Group Dose 
(mg/ea)
Time (day) Group 
(no./ea)
Tumor volume (mm
3) Inhibition (%)
c
Initial Final
Pancreatic placebo 0 28/60
a 10 168.12 ± 52.30
b 2195.62 ± 
832.62
b
CFPAC-1 tumo JF-10-81 5 28/60
49/60
10 196.90 ± 67.96 43.58 ± 14.13
8.30 ± 7.89
−92.44%
Neuoroblastoma placebo 0 42/60 6 758.12 ± 291.9 9097.9 ± 4928.52
IMR32 tumor JF-10-81 5 42/60 6 763.14 ± 217.75 1853.92 ± 815.96 86.92%
Leukemia placebo 0 35/60 6 393.35 ± 141.92 5615.32 ± 3143.98
MOLT-4 tumor JF-10-81 5 35/60 6 270.27 ± 88.65 429.76 ± 329.76 96.94%
Carcinoid placebo 0 42/60 8 58.49 ± 13.21 500.18 ± 160.68
Bon tumor JF-10-81 5 42/60 6 94.90 ± 17 161.6 ± 60.94 85%
Notes: 
a28/60 means that the pellet can continuously release drug for 60 days, actually, the experiments were terminated at 28 days.
bMean ± SEM.
cInhibition (%) = 100% *Treated Group (Final volume-Initial volume)/Control Group (Final volume-Initial volume).498
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The internalization assay demonstrated that this 
SSTR2-speciﬁ  c JF-10-81 could quickly be taken 
up in SSTR2-transfected cells. In our experience, 
a frequent low dose was found to work better than 
a less frequent high dose. In a previous study, 
JF-10-81 did not affect human prostate cancer PC-3 
tumor growth using a less frequent low dose pro-
tocol (0.73 mg/kg, twice a week) [9]. However, 
current results indicate that JF-10-81 obviously 
inhibited PC-3 tumor growth at the more frequent 
higher dose (3.5 mg/kg, 3 times a week), resulting 
in an almost 60% decrease in volume (Fig. 5). 
Taking these observations into account and the 
expectation that the targeted conjugate would have 
an improved therapeutic/toxicity ratio, an approach 
using a continuous drug-releasing pellet of 60 days 
was implemented. The results show that this new 
continuous drug-releasing approach results in sig-
niﬁ  cantly improved tumor responses and with no 
evidence of animal body weight losses. JF-10-81 
resulted in an over 85% reduction in tumors of 
neuroblastoma IMR32 and leukemia MOLT-4 with 
solid tumor regression and even disappearance of 
some CFPAC-1 tumors occurring. As for SSTR-
overexpressing, but CPT-insensitive BON tumors, 
JF-10-81 exhibited much more potent inhibitory 
effects with over double the inhibitory rate seen 
with the CPT formulation perhaps by increasing 
the CPT concentration within the vascularized solid 
tumor or possibly inside the tumor cells themselves 
(data not shown). And previously JF-10-81 also 
displayed anti-angiogenic activity in vitro [25], and 
now additionally showed its ability to inhibit the 
metastasis of the highly invasive PC-3 tumors 
(Fig. 5). Therefore, this conjugate JF-10-81 with 
optimal drug-releasing approach could be a new 
potential chemotherapeutics.
Reportedly, the cultured tumor cells IMR32 and 
CFPAC-1 highly express some SSTRs [33,39,40], 
with BON cells natively expressing high levels of 
SSTR1, SSTR2 and SSTR5 [41,42]. Our results are 
similar to the previous reports. Abundant SSTR2 
mRNAs were detected in all 5 cultured tumor cells 
and SSTR2 proteins were detected as well. How-
ever, except BON and IMR32 cells, we observed 
little or very weak binding afﬁ  nities of total 5 
SSTRs in CFPAC-1, MOLT-4, PC-3 and many other 
tumor cells. Somatostatin binding has been dem-
onstrated in tumor tissues taken from various pri-
mary tumors including neuroblastoma, pancreatic 
cancer, carcinoid and leukemia and prostate cancer 
[14]. Part of this problem may lie in the over 
passaging of commercially available cell lines and 
we have observed that native tumor cells and even 
receptor-transfected cells with initially high binding 
afﬁ  nity can gradually lose their receptor density 
and binding speciﬁ  city and rise non-speciﬁ  c bind-
ing after multiple passages. There is the possibility 
that cultured cells lose their natural in vivo micro-
environments that can stimulate expression of 
SSTRs and their functional appearance on cell 
surfaces. This and additional interactions with other 
cells or growth factors could be part of several pos-
sible explanations for why JF-10-81 had greater in 
vivo but less in vitro effects than naked CPT. Addi-
tionally, in animals the conjugate would have the 
ability to target and kill SSTR-positive tumor blood 
vessels thus providing an additional mechanism for 
inhibition of tumor growth [10].
In conclusion, this CPT-SST conjugate has been 
shown to effectively inhibit angiogenesis and the 
progression of various SSTR-positive tumors, with 
low toxicity. Apparently, through targeting receptor-
speciﬁ  c tumor sites, this kind of novel cytotoxic 
peptide conjugates can increase cancer cell 
selectivity and cytotoxicity and reduce toxic side 
effects relative to the traditional chemotherapy.
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